bidmark, the Vascepa Covid-19 trial bet was for pre-loading of vulnerable cohorts (medical workers/Argentina and Kaiser range of ages) to "minimize course of viral infection". For therapeutic treatment you would have to combine Vascepa with an antibody, which the trials do not carry.
At best this leaves Vascepa as an adjunct, to whatever will be Standard of Care for the in-hospital teams. The continuing vaccination drive has vastly diminished, if not obsoleted, our Covid19 market potential.
More on private in a couple of days.
Best,
News 
Market Data 
Discover 
AI
